Article
Cyclosporine offers new approach to dry eye treatment
Author(s):
Maui, HI-FDA approval of Restasis (cyclosporine ophthalmic emulsion, 0.05%, Allergan, Irvine, CA), in December opened a new door for patients with dry eye disease by offering two important "firsts": the drug provides more than palliation of dry eye symptoms, and it targets the inflammation that is the underlying cause of dry eye disease. It may even effect a cure in some patients. The drug became commercially available early last month.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
ImprimisRx offers a look at three new products in the pipeline
Visus CEO updates on lead product candidate, 2021 pipeline
(AAO) Genentech provides update on presentations, product portfolio
What keeps you up at night in ophthalmology: Part II
Glaucoma 360: Drug delivery contact lens technology
Glaucoma 360: Pharmaceuticals in the glaucoma industry
Related Content
